Patients were randomly allocated ( @:@ ) with a centralised , interactive voice-response system ( stratified by sex , region , performance status , and previous maintenance therapy -LSB- yes vs no -RSB- ) to receive docetaxel @ mg/m ( @ ) and either ramucirumab ( @ mg/kg ) or placebo on day @ of a @ day cycle until disease progression , unacceptable toxicity , withdrawal , or death .